{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:53Z","timestamp":1792788773320,"version":"4.5.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"name":"ORKID"},{"name":"GIRCI M\u00e9diterran\u00e9e","award":["18-GIRCI-03"],"award-info":[{"award-number":["18-GIRCI-03"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,11]]},"abstract":"\n Background and objectives<\/jats:title>\n Membranous nephropathy is a rare autoimmune kidney disease whose increasing prevalence in industrialized countries pleads for the involvement of an environmental factor in the development of the disease. In addition, the predominance of men in membranous nephropathy, classically attributed to biologic or genetic differences between men and women, could also be due to different occupational exposures. To support this hypothesis, we sought to describe the toxic occupational exposures of patients with membranous nephropathy.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n In this observational epidemiologic study, we compared the occupations and toxic occupational exposures of 100 patients with membranous nephropathy with those of the general population, consisting of two cohorts of 26,734,000 and 26,500 French workers. We then compared the characteristics of patients exposed to an occupational toxic substance with those of unexposed patients.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Patients with membranous nephropathy worked more frequently in the construction sector than the general population (33% versus 7%,\n P<\/jats:italic>\n <0.001). This difference remained significant by age and sex. They were also more frequently exposed to toxic substances, such as asbestos (16% versus 5%,\n P<\/jats:italic>\n <0.001), lead (9% versus 1%,\n P<\/jats:italic>\n <0.001), or organic solvents (37% versus 15%,\n P<\/jats:italic>\n <0.001), than the general population. The predominance of men in the subgroup of patients occupationally exposed to toxic substances was not observed in unexposed individuals (organic solvents: 80% men versus 41%,\n P<\/jats:italic>\n <0.001; asbestos: 90% men versus 55%,\n P<\/jats:italic>\n =0.004). In addition, patients with phospholipase A2 receptor 1 (PLA2R1) epitope spreading were more frequently exposed to asbestos and organic solvents than patients without epitope spreading (32% versus 7%,\n P<\/jats:italic>\n =0.02 and 74% versus 43%,\n P<\/jats:italic>\n =0.02, respectively), with a dose-dependent effect.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Patients with membranous nephropathy were more frequently exposed to certain occupational toxic substances, such as asbestos and organic solvents, than the general population. This occupational exposure was more frequent in men and in patients with PLA2R1 epitope spreading.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n Immunopathological Analysis in a French National Cohort of Membranous Nephropathy (IHMN), NCT04326218.<\/jats:p>\n <\/jats:sec>\n \n Podcast<\/jats:title>\n This article contains a podcast at https:\/\/www.asn-online.org\/media\/podcast\/CJASN\/2022_10_25_CJN02930322.mp3.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.02930322","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T08:27:38Z","timestamp":1667204858000},"page":"1609-1619","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Toxic Occupational Exposures and Membranous Nephropathy"],"prefix":"10.2215","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct04326218","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5837-9469","authenticated-orcid":false,"given":"Marion","family":"Cremoni","sequence":"first","affiliation":[{"name":"Reference Center for Rare Diseases Idiopathic Nephrotic Syndrome, Nice University Hospital, Nice, France"},{"name":"Clinical Research Unit C\u00f4te d\u2019Azur, University C\u00f4te d\u2019Azur, Nice, France"},{"name":"Department of Nephrology Dialysis and Transplantation, Pasteur 2 Hospital, Nice University Hospital, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Agbekodo","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Cimiez Hospital, Nice University Hospital, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Teisseyre","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases Idiopathic Nephrotic Syndrome, Nice University Hospital, Nice, France"},{"name":"Clinical Research Unit C\u00f4te d\u2019Azur, University C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Zorzi","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases Idiopathic Nephrotic Syndrome, Nice University Hospital, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Brglez","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases Idiopathic Nephrotic Syndrome, Nice University Hospital, Nice, France"},{"name":"Clinical Research Unit C\u00f4te d\u2019Azur, University C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Benzaken","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Archet 1 Hospital, Nice University Hospital, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Esnault","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases Idiopathic Nephrotic Syndrome, Nice University Hospital, Nice, France"},{"name":"Department of Nephrology Dialysis and Transplantation, Pasteur 2 Hospital, Nice University Hospital, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Hanna","family":"Planchard","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Cimiez Hospital, Nice University Hospital, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases Idiopathic Nephrotic Syndrome, Nice University Hospital, Nice, France"},{"name":"Clinical Research Unit C\u00f4te d\u2019Azur, University C\u00f4te d\u2019Azur, Nice, France"},{"name":"Department of Nephrology Dialysis and Transplantation, Pasteur 2 Hospital, Nice University Hospital, Nice, France"},{"name":"Immunology Laboratory, Archet 1 Hospital, Nice University Hospital, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.nephro.2014.08.002","article-title":"The essential of 2012 results from the French Renal Epidemiology and Information Network (REIN) ESRD registry","volume":"11","author":"Lassalle","year":"2015","journal-title":"Nephrol Ther"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: From models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J Clin Invest"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fmed.2019.00241","article-title":"Immune-monitoring disease activity in primary membranous nephropathy","volume":"6","author":"Cravedi","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1111\/j.1523-1755.2005.09711.x","article-title":"Hygiene hypothesis and prevalence of glomerulonephritis","volume":"68","author":"Hurtado","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2215\/CJN.00710805","article-title":"Changing incidence of glomerular disease in Olmsted County, Minnesota: A 30-year renal biopsy study","volume":"1","author":"Swaminathan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12916-015-0306-7","article-title":"Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: Origins, pathophysiology, and clinical applications","volume":"13","author":"Versini","year":"2015","journal-title":"BMC Med"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2012070730","article-title":"Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy","volume":"24","author":"Coenen","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1681\/ASN.2012080771","article-title":"Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy","volume":"24","author":"Lv","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2215\/CJN.05310513","article-title":"HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy","volume":"9","author":"Bullich","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1681\/ASN.2016020114","article-title":"MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy","volume":"28","author":"Cui","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1681\/ASN.2016060644","article-title":"HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-related membranous nephropathy","volume":"28","author":"Le","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10157-017-1471-0","article-title":"Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy","volume":"22","author":"Kaga","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41467-020-15383-w","article-title":"The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis","volume":"11","author":"Xie","year":"2020","journal-title":"Nat Commun"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature","volume":"15","author":"Roccatello","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3389\/fimmu.2020.01777","article-title":"Myeloid-derived suppressor cells promote the progression of primary membranous nephropathy by enhancing Th17 response","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"574997","DOI":"10.3389\/fimmu.2020.574997","article-title":"Th17-immune response in patients with membranous nephropathy is associated with thrombosis and relapses","volume":"11","author":"Cremoni","year":"2020","journal-title":"Front Immunol"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"155452","DOI":"10.1016\/j.cyto.2021.155452","article-title":"Altered Th17\/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy","volume":"141","author":"Motavalli","year":"2021","journal-title":"Cytokine"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"665629","DOI":"10.3389\/fimmu.2021.665629","article-title":"Helper T cells in idiopathic membranous nephropathy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrneph.2018.11","article-title":"Environmental pollution and kidney diseases","volume":"14","author":"Xu","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2215\/CJN.07571009","article-title":"Mercury-induced membranous nephropathy: Clinical and pathological features","volume":"5","author":"Li","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/qjmed\/hcq209","article-title":"Membranous nephropathy after use of UK-manufactured skin creams containing mercury","volume":"104","author":"Chakera","year":"2011","journal-title":"QJM"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-120-5-199403010-00007","article-title":"Membranous nephropathy and formaldehyde exposure","volume":"120","author":"Breysse","year":"1994","journal-title":"Ann Intern Med"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"e51506","DOI":"10.1371\/journal.pone.0051506","article-title":"Organic solvents as risk factor for autoimmune diseases: A systematic review and meta-analysis","volume":"7","author":"Barrag\u00e1n-Mart\u00ednez","year":"2012","journal-title":"PLoS One"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.autrev.2013.10.002","article-title":"Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature","volume":"13","author":"Marie","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1203475420957950","article-title":"Toward understanding of environmental risk factors in systemic sclerosis","volume":"25","author":"Ouchene","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/00039896.1972.10666187","article-title":"Glomerulonephritis associated with hydrocarbon solvents: Mediated by antiglomerular basement membrane antibody","volume":"25","author":"Beirne","year":"1972","journal-title":"Arch Environ Health"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0140-6736(75)90671-6","article-title":"Hydrocarbon exposure and chronic glomerulonephritis","volume":"2","author":"Zimmerman","year":"1975","journal-title":"Lancet"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/01.ASN.0000103872.60993.06","article-title":"Absence of association between organic solvent exposure and risk of chronic renal failure: A nationwide population-based case-control study","volume":"15","author":"Fored","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B36-20241015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1681\/ASN.2006060652","article-title":"Effect of organic solvent exposure on chronic kidney disease progression: The GN-PROGRESS cohort study","volume":"18","author":"Jacob","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B37-20241015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/oem.2007.032482","article-title":"New insight into solvent-related end-stage renal disease: Occupations, products and types of solvents at risk","volume":"64","author":"Jacob","year":"2007","journal-title":"Occup Environ Med"},{"key":"B38-20241015","doi-asserted-by":"crossref","first-page":"J177","DOI":"10.1016\/j.jaut.2011.11.007","article-title":"Gender differences in autoimmunity associated with exposure to environmental factors","volume":"38","author":"Pollard","year":"2012","journal-title":"J Autoimmun"},{"key":"B39-20241015","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B40-20241015","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.2215\/CJN.07300619","article-title":"Does epitope spreading influence responsiveness to rituximab in PLA2R-associated membranous nephropathy?","volume":"14","author":"Salant","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B41-20241015","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B42-20241015","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B43-20241015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2215\/CJN.10240819","article-title":"Management of membranous nephropathy after MENTOR","volume":"15","author":"Trivin-Avillach","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B44-20241015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.toxlet.2012.09.018","article-title":"Cytokine expression in trichloroethylene-induced hypersensitivity dermatitis: An in vivo and in vitro study","volume":"215","author":"Jia","year":"2012","journal-title":"Toxicol Lett"},{"key":"B45-20241015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.0954-6820.1976.tb08257.x","article-title":"Nephrotic syndrome due to subacute glomerulonephritis\u2014Association with hydrocarbon exposure?","volume":"200","author":"von Sch\u00e9ele","year":"1976","journal-title":"Acta Med Scand"},{"key":"B46-20241015","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0140-6736(79)91875-0","article-title":"Improvement of glomerulonephritis after discontinuation of solvent exposure","volume":"1","author":"Ravnskov","year":"1979","journal-title":"Lancet"},{"key":"B47-20241015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000183476","article-title":"Proliferative glomerulonephritis and exposure to organic solvents","volume":"40","author":"Bell","year":"1985","journal-title":"Nephron"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.02930322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:46Z","timestamp":1786369486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.02930322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02930322","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"2022-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}